Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSND-201 in PTSD
NCT07456696Phase 3Recruiting
- Sponsor
- Transcend Therapeutics
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of TSND-201 in post-traumatic stress disorder (PTSD) (3 arms), sponsored by Transcend Therapeutics. Primary endpoint: Clinician-Administered PTSD Scale for DSM-5 Total Severity Score at 12 weeks. Started Apr 2026; status: recruiting.
02
Drugs
TSND-201
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT07456696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07456696.